In Silico Analysis Of A Human Cardiac Adverse Effects Data Set.pdf
Previously, we have shown that structural alerts for the prediction of HERG channel inhibition can be developed from the results of in vitro studies. We were therefore interested to see if a similar methodology could also be applied to the derivation of predictive models from a data set of human cardiac post-marketing adverse effects data, containing information on 14 endpoints such as bradycardia and QT prolongation (provided through a Cooperative Research and Development Agreement between Lhasa Limited and the US Food and Drug Administration*) .
Poster presented by Laura Gibson at the 13th International Conference on Drug-Drug Interations (DDI) / 8th International Conference on Early Toxicity Screening (ETS), Seattle, USA; 14th - 18th June 2010.
*This research report is not an official US Food and Drug Administration guidance or policy statement. No official
support or endorsement by the US Food and Drug Administration is intended or should be inferred.